Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EsV3 is a bioactive dietary supplement and protein fraction derived from the earthworm *Eisenia fetida*. It is primarily investigated for its cardioprotective and vasculoprotective properties, particularly in the context of atherosclerosis and hyperlipidemia. EsV3 is characterized as a component of earthworm fibrinolytic enzymes (EFEs) and has demonstrated the ability to reduce atherosclerotic plaque formation and stabilize lipid profiles in preclinical models, such as apolipoprotein E (ApoE) deficient mice. Its therapeutic mechanism involves multi-pathway action, including fibrinolytic activity (degrading fibrin and fibrinogen), antioxidant effects that mitigate oxidative damage, and anti-inflammatory properties that inhibit the progression of vascular lesions. It is positioned as a potential natural alternative or adjunctive therapy for managing cardiovascular risks associated with high-fat diets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on EsV3.